1. Home
  2. FSP vs MDWD Comparison

FSP vs MDWD Comparison

Compare FSP & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

N/A

Current Price

$0.64

Market Cap

64.7M

Sector

Real Estate

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

N/A

Current Price

$16.88

Market Cap

224.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSP
MDWD
Founded
1981
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.7M
224.6M
IPO Year
2001
2013

Fundamental Metrics

Financial Performance
Metric
FSP
MDWD
Price
$0.64
$16.88
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
608.2K
67.9K
Earning Date
03-09-2026
03-05-2026
Dividend Yield
6.97%
N/A
EPS Growth
15.69
N/A
EPS
N/A
N/A
Revenue
$107,162,000.00
N/A
Revenue This Year
$17.91
$57.63
Revenue Next Year
N/A
$26.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$14.14
52 Week High
$1.89
$22.51

Technical Indicators

Market Signals
Indicator
FSP
MDWD
Relative Strength Index (RSI) 46.49 41.49
Support Level N/A N/A
Resistance Level $0.86 $18.58
Average True Range (ATR) 0.05 0.56
MACD 0.00 -0.03
Stochastic Oscillator 54.70 13.60

Price Performance

Historical Comparison
FSP
MDWD

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: